- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.02. | Modus Therapeutics Holding AB: Modus Therapeutics publishes year-end report for 2025 | 1.072 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 25 February 2026: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes year-end report for 2025. The report is available on the company's website (www.modustx.com)... ► Artikel lesen | |
| 10.12.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics initiates dosing in phase 2a study in patients with chronic kidney disease with anemia | 261 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in the phase 2a... ► Artikel lesen | |
| 26.11.25 | Modus Therapeutics Holding AB: Modus Therapeutics publishes Interim report for the third quarter 2025 | 478 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 26 November 2025: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes an interim report for the third quarter of 2025. The report is available on the company's... ► Artikel lesen | |
| MODUS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 04.11.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia | 262 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN November 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate... ► Artikel lesen | |
| 03.11.25 | Modus Therapeutics Holding AB: Modus Therapeutics receives regulatory approval for Part 2 of the Phase IIa study in CKD-with anemia | 282 | GlobeNewswire (Europe) | Stockholm, Sweden - November 3, 2025- Modus Therapeutics Holding AB (publ) ("Modus" or the "Company") announces that the competent authorities in Italy have approved the Company's dose selection for... ► Artikel lesen | |
| 28.08.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics raises SEK 28.3 million in oversubscribed unit issue | 187 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN August 28, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has raised SEK 28.3 million in a unit issue with... ► Artikel lesen | |
| 07.08.25 | Modus Therapeutics Holding AB: Modus Therapeutics publishes Interim report for the second quarter 2025 | 440 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 7 August 2025: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes an interim report for the second quarter of 2025. The report is available on the company's website... ► Artikel lesen | |
| 06.08.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.08.2025 | 539 | Xetra Newsboard | Das Instrument 9YG NO0010955917 DEEP VAL.DRILL.AS NK -,10 EQUITY wird cum Kapitalmassnahme gehandelt am 06.08.2025 und ex Kapitalmassnahme am 07.08.2025 The instrument 9YG NO0010955917 DEEP VAL.DRILL.AS... ► Artikel lesen | |
| 01.08.25 | Modus Therapeutics Holding AB: Modus Therapeutics on track to initiate Part 2 of Phase IIa sevuparin study in CKD-related anemia | 404 | GlobeNewswire (Europe) | Stockholm, Sweden - 1 August 2025 - Modus Therapeutics Holding AB (publ) ("Modus") today announces that dose levels for Part 2 of its ongoing Phase IIa clinical study of sevuparin in patients with chronic... ► Artikel lesen | |
| 29.07.25 | Modus Therapeutics Holding AB: Extraordinary General Meeting in Modus Therapeutics Holding AB (publ) | 261 | GlobeNewswire (Europe) | Modus Therapeutics' Extraordinary General Meeting on 29 July 2025 resolved in accordance with the following:
To amend the company's articles of association in order to increase the limits of the company's... ► Artikel lesen | |
| 14.07.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics completes enrollment in part 1 of its phase 2a study with sevuparin | 419 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN July 14, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has completed patient enrollment on schedule to part... ► Artikel lesen | |
| 08.07.25 | Modus Therapeutics Holding AB: Modus Therapeutics completes enrollment in Part 1 of the Phase IIa sevuparin study in chronic kidney disease with anemia | 309 | GlobeNewswire (Europe) | Stockholm, Sweden - 8 July 2025 - Modus Therapeutics Holding AB (publ) ("Modus") today announces that patient enrollment in Part 1 of its ongoing Phase IIa study evaluating sevuparin for the treatment... ► Artikel lesen | |
| 27.06.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics carries out a fully secured rights issue of SEK 28.3 million | 115 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN June 27, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics carries out a fully secured rights issue of units... ► Artikel lesen | |
| 14.05.25 | Modus Therapeutics Holding AB: Modus Therapeutics publishes Interim report for the first quarter 2025 | 581 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 14 May 2025: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes an interim report for the first quarter of 2025. The report is available on the company's website... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,515 | -0,98 % | Aktien KW 17 Märkte im Würgegriff. Planloser Trump , selbstbewusterer Iran. Lösungen müssen her. News. Rheinmetall. ITM Power. Porsche. The Platform Group. K+S. Bugatti. Circus. Surteco. NanoRepro. BB Biotech. Mensch und Maschine. ATOSS. MHP Hotel | Aktien - letzte Woche warteten die Märkte auf eine Lösung des Iran-Kriegs. Aber die Iraner sehen sich im Vorteil und Trump verlängert "auf unbestimmte Zeit" den Waffenstillstand. Aber die Strasse von... ► Artikel lesen | |
| MARINOMED BIOTECH | 12,500 | -2,34 % | EQS-NVR: Marinomed Biotech AG: Veröffentlichung der Gesamtstimmrechte nach § 135 Abs. 1 BörseG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Marinomed Biotech AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Marinomed Biotech AG: Veröffentlichung der Gesamtstimmrechte nach § 135... ► Artikel lesen | |
| REPLENISH NUTRIENTS | 0,077 | -7,23 % | Replenish Nutrients Holding GAAP EPS of -$0.03, revenue of $2.96M | ||
| SANA BIOTECHNOLOGY | 3,270 | -0,61 % | Sana Biotechnology stellt präklinische Daten zu CAR-T-Therapiekandidat auf Fachtagung vor | ||
| NOVABRIDGE BIOSCIENCES | 1,990 | -7,01 % | NovaBridge Biosciences: NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update | Successful transformation to global biotech platform with two mid-stage potential best-in-class/first-in-class programs, givastomig and VIS-101, with compelling proof-of-concept dataGivastomig, a... ► Artikel lesen | |
| GENEURO | 0,000 | -100,00 % | GeNeuro SA Announces the End of the Debt Moratorium and the Commencement of Bankruptcy Proceedings | Regulatory News:
GeNeuro SA (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, announces that the Geneva... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,115 | -24,94 % | Summit Therapeutics falls after update on Akeso-partnered lung cancer trial | ||
| ERASCA | 10,000 | -6,10 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| RELAY THERAPEUTICS | 12,720 | -1,85 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer | Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,960 | -3,05 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| COGENT BIOSCIENCES | 36,630 | +2,35 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 323,50 | +1,46 % | Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide | ||
| JANUX THERAPEUTICS | 14,340 | -0,21 % | Janux Therapeutics, Inc. - 8-K, Current Report | ||
| KINIKSA PHARMACEUTICALS | 55,23 | +2,70 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $930 - $945 million -- KPL-387... ► Artikel lesen | |
| CG ONCOLOGY | 66,21 | -0,79 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen |
MODUS THERAPEUTICS HOLDING AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,030 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MODUS THERAPEUTICS HOLDING AB finden Sie auf Wallstreet Online.